A Serological Diagnostic Immunoassay Test Strip for Leishmaniasis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$285,879.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI078569-01
Award Id:
88754
Agency Tracking Number:
AI078569
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
INTELLIGENT OPTICAL SYSTEMS, INC., 2520 W 237TH ST, TORRANCE, CA, 90505
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
033449757
Principal Investigator:
() -
Business Contact:
() -
shonda@intopsys.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Leishmaniasis is a disease endemic to India, Africa, Mediterranean nations, South American countries, and southern Texas. Americans visiting Latin American nations as tourists, and soldiers serving in Iraq and Afghanist an, have contracted the disease. Polymerase chain reaction (PCR) and enzyme immunosorbent assays (ELISA) are commonly used to diagnose this disease. The current methods are laboratory based, require special equipment, involve complex procedures, and are la bor intensive and time-consuming. ELISA tests for leishmaniasis are not highly specific and sensitive, so there is an important need to develop easy-to- use and highly sensitive diagnostic tests for leishmaniasis. In this project, Intelligent Optical Syste ms, in collaboration with Professor Diane McMahon-Pratt of the Yale University School of Medicine, proposes to develop an easy-to-use and highly sensitive lateral flow immuno assay test strip for the accurate diagnosis of leishmaniasis. The conventional ap proach for developing immunoassays for leishmaniasis involves the use of total Leishmania promastigotes as antigens. Using these antigens in the assay reduces the sensitivity, and also causes a cross reactivity problem with related diseases, such as Chagas disease. This project involves the development of a more sensitive and specific lateral flow immunoassay that will utilize highly specific heat shock proteins as antigens. These antigens will be used, in conjunction with quantum dots labels, to achieve hi gh sensitivity. In Phase I, IOS will demonstrate the superior performance of this assay over the ELISA kits currently used for cutaneous leishmaniasis diagnosis. The use of quantum dots as labels will allow additional antigens to be incorporated, in the fu ture, to develop a multiplexed lateral flow immunoassay. PUBLIC HEALTH RELEVANCE: Leishmaniasis affects millions of people and causes thousands of deaths annually. Unfortunately, current methods of diagnosis involve labor intensive laboratory based procedu res, and are not sufficiently sensitive or specific. This application describes a novel method to develop a simple, field-usable, sensitive, and highly specific test kit for leishmaniasis diagnosis.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government